Huma has raised $80 million in fourth-round financing that will go in part towards rolling out a new platform that can be used by developers to create disease management tools.
Mere months after announcing a partnership to develop digital support tools for cancer patients, Huma Therapeutics and Merck KGaA have launched their first app in the UK.
Huma Therapeutics has been granted Class II clearance from the FDA for its Software-as-a-Medical-Device (SaMD) disease management platform, dramatically expanding the rang
AstraZeneca has bought a stake in digital health firm Huma Therapeutics in a deal that will see ownership of AZ's AMAZE disease management platform transfer to the UK startup.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.